Compare DLPN & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | ITRM |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 24.3M |
| IPO Year | 2008 | 2018 |
| Metric | DLPN | ITRM |
|---|---|---|
| Price | $1.61 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 42.1K | ★ 656.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.81 | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,684,984.00 | N/A |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $13.78 | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $0.75 | $0.20 |
| 52 Week High | $1.88 | $1.49 |
| Indicator | DLPN | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 53.56 |
| Support Level | $1.46 | $0.27 |
| Resistance Level | $1.73 | $0.39 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.33 | 83.76 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.